logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5758.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Export All Citations
Copyright © Médecins Sans Frontières
v2.1.5758.produseast1
Showing 1 - 7 of 7 Items
Showing 1 - 7 of 7 Items
Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.
  • Current Page (7)
  • CSV
  • BibTeX
  • EndNote
  • All Results (7)
  • CSV
  • BibTeX
  • EndNote
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis

Garcia-Prats AJ, Garcia-Cremades M, Cox V, Kredo T, Dunbar R,  et al.
2025-02-01 • Lancet Child and Adolescent Health
2025-02-01 • Lancet Child and Adolescent Health

BACKGROUND

There are few data on the treatment of children and adolescents with multidrug-resistant (MDR) or rifampicin-resistant (RR) tuberculosis, especially ...

Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Review
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Commentary

A bitter pill to swallow: the need for better medications for drug-resistant tuberculosis in children

Furin J, Mafukidze A, Brigden G, du Cros PAK, Golin R,  et al.
2015-12-01 • International Journal of Tuberculosis and Lung Disease

Clinical standards for drug-susceptible TB in children and adolescents

Chiang SS, Graham SM, Schaaf HS, Marais BJ, Sant’Anna CC,  et al.
2023-08-01 • International Journal of Tuberculosis and Lung Disease
2023-08-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
These clinical standards aim to provide guidance for diagnosis, treatment, and management of drug-susceptible TB in children and adolescents.

METHODS
Fifty-tw...

The devil we know: is the use of injectable agents for the treatment of MDR-TB justified?

Reuter A, Tisile P, von Delft D, Cox HS, Cox V,  et al.
2017-11-01 • International Journal of Tuberculosis and Lung Disease
2017-11-01 • International Journal of Tuberculosis and Lung Disease
For decades, second-line injectable agents (IAs) have been the cornerstone of treatment for multidrug-resistant tuberculosis (MDR-TB). Although evidence on the efficacy of IAs is limited...

New and repurposed drugs for pediatric multidrug-resistant tuberculosis. Practice-based recommendations

Harausz EP, Garcia-Prats AJ, Seddon JA, Schaaf HS, Hesseling AC,  et al.
2016-11-17 • American Journal of Respiratory and Critical Care Medicine
2016-11-17 • American Journal of Respiratory and Critical Care Medicine
It is estimated that 33,000 children develop multidrug-resistant tuberculosis (MDR-TB) each year. In spite of these numbers, children and adolescents have limited access to the new and r...

Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa

Mohr-Holland E, Reuter A, Furin J, Garcia-Prats AJ, De Azevedo V,  et al.
2020-03-01 • eClinicalMedicine
2020-03-01 • eClinicalMedicine
BACKGROUND
Limited data exist on the use of bedaquiline and delamanid in adolescents with rifampicin-resistant tuberculosis (RR-TB). We describe RR-TB treatment of adolescents (10-19...

Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis

Harausz EP, Garcia-Prats AJ, Law S, Schaaf HS, Kredo T,  et al.
2018-07-11 • PLOS Medicine
2018-07-11 • PLOS Medicine
An estimated 32,000 children develop multidrug-resistant tuberculosis (MDR-TB; Mycobacterium tuberculosis resistant to isoniazid and rifampin) each year. Little is known about the optima...
2015-12-01 • International Journal of Tuberculosis and Lung Disease